Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C1762617 (
weakness
)
37,932
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Generalized muscle weakness
culminating in ventilatory failure developed in a 59-year-old man with kappa light chain multiple myeloma. Physical examination demonstrated skeletal muscle enlargement, severe proximal muscle
weakness
, and macroglossia, consistent with amyloid-associated muscle pseudohypertrophy. Pulmonary function studies revealed a severe restrictive abnormality with a low maximal inspiratory pressure and maximal voluntary ventilation. Arterial blood gas values and chest radiographic results were normal. There was no clinical evidence of cardiac or central nervous system disease. At autopsy, skeletal muscles and diaphragm were diffusely infiltrated by amyloid. There was also multifocal deposition of amyloid in alveolar septae, esophagus, and subendocardium. This report suggests that ventilatory failure may occur as a complication of myeloma-associated (AL) amyloidosis involving the respiratory muscles.
...
PMID:Respiratory muscle weakness and ventilatory failure in AL amyloidosis with muscular pseudohypertrophy. 311 Dec 59
Generalized muscle weakness
in critically ill patients can result in prolonged periods of artificial ventilation and longer stays in the intensive care unit. Both neuropathic (critical illness polyneuropathy) and myopathic (critical illness myopathy) abnormalities seem to play an important role for this prolonged
weakness
. This article reviews its complex differential diagnosis with special emphasis on the current understanding of the neuromuscular syndromes. An efficient diagnostic plan is necessary for the exclusion of other curable causes of prolonged muscle
weakness
even in the presence of polyneuromyopathic changes. Psychological support of the patient and prophylaxis of secondary complications of prolonged immobilization are crucial when specific therapy is not possible.
...
PMID:[Prolonged muscle weakness in intensive care patients with special attention to the so-called intensive care polyneuromyopathy]. 916 66
Acute fulminating myasthenia gravis (MG) was diagnosed in 5 dogs. Acute fulminating generalized MG in dogs is characterized by sudden onset of megaesophagus and frequent regurgitation of large volumes of fluid.
Generalized muscle weakness
can worsen and lead to recumbency within days. Despite appropriate supportive care,
weakness
is not alleviated by rest. Respiratory failure caused by aspiration pneumonia and loss of strength in muscles involved with respiration is a common cause of death. In dogs with acute onset of regurgitation, MG should be considered as a differential diagnosis. Clinicians should be aware of the risk of rapid progression to quadriparesis if aspiration pneumonia develops.
...
PMID:Acute fulminating myasthenia gravis in five dogs. 953 Apr 21
Generalized muscle weakness
is a common disorder in patients undergoing mechanical ventilation. The cause is unknown but is attributed to the administration of non-depolarizing neuromuscular blocking and other drugs, mainly steroids, or to the presence of sepsis or multiorgan failure. Specific clinical pictures (polyneuropathy, myopathy and prolonged muscle
weakness
) develop in function of the underlying cause, although etiological factors may sometimes interact. Differential diagnosis is carried out with the aid of electromyography and pathology of the peripheral muscle. Costs are high and prognosis is uncertain. Completeness of neuromuscular blockade must be monitored in these patients to guide the administration of drugs, to avoid overdoses, to maintain muscle activity and to detect a chain of reactions among concomitant medications or pathophysiologic changes.
...
PMID:[Prolonged muscle weakness associated with the administration of non-depolarizing neuromuscular blocking agents in critically ill patients]. 1167 84
Chronic obstructive pulmonary disease, COPD is a highly prevalent disorder of increasing medical and socio-economical importance. It is characterized by irreversible airflow obstruction. Besides airflow obstruction also other features are present. One of these is respiratory muscle
weakness
. Inspiratory muscle
weakness
is caused by hyperinflation and by generalized muscle
weakness
causing both respiratory and peripheral muscle dysfunction. The expiratory muscles partake in this generalized muscle
weakness
. Hyperinflation shortens the inspiratory muscles although in chronic hyperinflation sarcomere adaptation occurs.
Generalized muscle weakness
is caused by deconditioning, malnutrition, electrolyte disturbances, cardiac failure, systemic inflammation and treatment with corticosteroids causing steroid-induced myopathy. The latter disease was studied intensively both in patients and in animal models of disease. The major findings were that microscopically a myopathic pattern was present associated with generalized fiber atrophy. This is in contrast to classical belief that the atrophy would be confined to type IIx fibers. We noted severe down-regulation of the IGF-I mRNA expression, without important changes in the expression of the binding proteins. This may be responsible for the observed muscle atrophy and the myopathy. The latter is likely to be caused by a simultaneous upregulation of the ubiquitin protease pathway attacking structural proteins. Presently, we study the relationship between local and systemic cytokine expression and respiratory and peripheral muscle dysfunction in COPD patients. Respiratory and peripheral muscle dysfunction have significant consequences for COPD patients. Both respiratory and peripheral muscle dysfunction are associated with reduced exercise tolerance and reduced quality of life. Both are independent determinants of survival, in addition to the degree of airflow obstruction as measured by FEV1. Finally, also the utilization of health care resources appeared to be related to respiratory and peripheral muscle
weakness
. Treatment of respiratory and peripheral muscle
weakness
in COPD patients is possible. Respiratory and peripheral muscle training have been shown to produce beneficial effects. Nutritional intervention and anabolic steroids are only useful in combination with muscle training. Systemic administration of growth hormone and IGF-I only produces small effects. In animal models, local administration of IGF-I and transfer of the IGF-I gene transfer appear more promising for the future. Lung volume reduction surgery, LVRS, improves the force-generating capacity of the inspiratory muscles, presumably because of the geometrical alterations it causes in these muscles. It does not appear to improve intrinsic inspiratory muscle function.
...
PMID:Respiratory muscles in COPD: regulation of trophical status. 1181 11
Inflammatory myopathies are a heterogeneous group of conditions characterized by proximal muscle
weakness
, nonsuppurative inflammation of skeletal muscle, with elevated muscle enzyme levels and characteristic electromyography and muscle biopsy findings. The authors describe a clinical case of a young woman, admitted with a four day history of bilateral thigh myalgia. She was afebrile and without skin, mucosal or joint involvement. Thigh muscle palpation was painful. Complete blood count revealed leukopenia and thrombocytopenia. High levels of creatine kinase, serum aminotransferases and myoglobin were detected. Metabolic, toxic and drug-related causes were excluded as well as infectious diseases, malignant tumours and endocrine myopathies. Auto-antibodies for connective diseases were negative. Magnetic resonance imaging and electromyography of lower limbs were suggestive of inflammatory myopathy.
Generalized muscle weakness
and dysphagia were reported subsequently. Clinical and laboratorial improvement was seen after corticotherapy. Muscle biopsy revealed myopathy signs without inflammatory changes or vasculitis. After prednisolone reduction, presently without treatment, she remains asymptomatic with normal laboratorial findings. The authors emphasize in this case of inflammatory myopathy the unusual clinical and laboratory evolution and the importance of a cautious differential diagnosis.
...
PMID:[Inflammatory myopathy with an unusual evolution]. 2071 Oct 99